Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting

Drug Development and Industrial Pharmacy

Volumn 35, Issue 11, 2009, Pages 1348-1355

  Lin, Aihua ^a   Chen, Jun ^b   Liu, Yiming ^a   Deng, Shigui ^a   Wu, Zhifeng ^a   Huang, Yu ^a   Ping, Qineng ^c  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Glycyrrhizin; Hepatocyte targeting; N caproyl chitosan; Nanoparticle; Surface modification; Tissue distribution

Indexed keywords

CHITOSAN DERIVATIVE; DOXORUBICIN; GLYCYRRHIZIC ACID; N HEXANOYLCHITOSAN; NANOPARTICLE; PERIODATE; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL BINDING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ELECTROCHEMISTRY; HEART; HUMAN; KIDNEY; LIVER; LIVER CELL; LUNG; MOUSE; NONHUMAN; OXIDATION; PARTICLE SIZE; RAT; SPLEEN; SURFACE PROPERTY; TARGET CELL; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ANIMALS; CHITOSAN; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FLOW CYTOMETRY; GLYCYRRHIZIC ACID; HEPATOCYTES; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED STRAINS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 70350346108     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040902939197     Document Type: Article

References (24)

1. Torchilin VP. (2005). Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv Drug Deliv Rev, 57:95-109.
2. Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, Tan P, et al. (2000). Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J Control Release, 65:203-220
3. Balthasar S, Michaelis K, Dinauer N, Von Briesen H, Kreuter J, Langer K. (2005). Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials, 26:2723-2732
4. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. (1997). Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci, 4:509-513
5. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y. (2001). Chitosan-DNA nanoparticles as gene carriers: Synthesis, characterization and transfection efficiency. J Control Release, 70:399-421.
6. Aktas Y, Andrieux K, Alonso MJ, Calvo P, Gürsoy RN, Couvreur P, et al. (2005). Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm, 298:378-383
7. Chan P, Kurisawa M, Chung JE, Yang YY. (2007). Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials, 28:540-549
8. Kim TH, Nah JW, Cho MH, Park TG, Cho CS. (2006). Receptor mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol, 6:2796-2803
9. Jiang H-L, Kwon J-T, Kim Y-K, Kim E-M, Arote R, Jeong H-J, et al. (2007). Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther, 14:1389-1398
10. Mao SJ, Hou SX, Zhang LK, Wei DP, Bi YQ. (2005). Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes. World J Gastroenterol, 28:3075-3079
11. Negishi M, Irie A, Nagata N, Ichikawa A. (1991). Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta, 1066:77-82.
12. Ismair MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak- Ublick GA. (2003). Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol Res, 26:343-347
13. Lin AH, Liu YM, Ping QN. (2007). Preparation and characterization of adriamycin-loaded chitosan nanoparticles surfacemodified with glycyrrhizin. J China Pharm Uni, 38:507-511
14. Lin AH, Liu YM, Ping QN. (2007). Studies of free amino groups on the surface of chitosan nanoparticles and its characteristics. Yao Xue Xue Bao, 42:323-328
15. Lin AH, Liu YM, Huang Y, Sun JB, Wu ZF, Zhang X, et al. (2008). Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharm, 359:247-253
16. Lee KY, Ha WS, Park WH. (1995). Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials, 16:1211-1216
17. Lee DW, Powers K, Baney R. (2004). Physicochemical properties and blood compatibility of acylated chitosan nanoparticles. Carbohyd polym, 58:371-377
18. Tien CL, Lacroix M, Ispas-Szabo P, Mateescu M. (2003). N-acylated chitosan: Hydrophobic matrices for controlled drug release. J control Release, 93:1-13.
19. Gupta PK, Hung CT. (1989). Quantitative evaluation of targeted drug delivery systems. Int J Pharm, 56:217-226
20. Nguyen LT, Ishida T, Ukitsu S, Li WH, Tachibana R, Kiwada H. (2003). Culture time-dependent gene expression in isolated primary cultured rat hepatocytes by transfection with the cationic liposomal vector TFL-3. Biol Pharm Bull, 26:880-885
21. Remant Bahadur KC, Aryal S, Bhattarai SR, Bhattarai N, Kim CH, Kim HY. (2006). Stabilization of gold nanoparticles by hydrophobically-modified polycations. J Biomater Sci Polym Ed, 17:579-589
22. López-León T, Carvalho ELS, Seijo B, Ortega-Vinuesa JL, Bastos-González D. (2005). Physicochemical characterization of chitosan nanoparticles: Electrokinetic and stability behavior. J Colloid Interface Sci, 283:344-351
23. Fernàndez-Urrusuno R, Calvo P, Remu5án-López C, Vila-Jato JL, Alonso MJ. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 16:1576-1581
24. Yu JJ, Lee HA, Kim JH, Kong WH, Kim Y, Cui ZY, et al. (2007). Biodistribution and antitumor efficacy of PEG/PLA nanoparticles loaded doxorubicin. J Drug Target, 15:279-284